YOUR BRAND · YOUR CUSTOMERS · YOUR AI BUSINESS

Sell AI employees under your own brand.

Agentic AI Comparison:
Google AI Co-Scientist vs Isomorphic Labs

Google AI Co-Scientist - AI toolvsIsomorphic Labs logo

Introduction

Google AI co-scientist is a multi-agent research system that helps scientists develop, critique and rank hypotheses and experimental proposals. Isomorphic Labs is an AI drug-design company developing therapeutics through internal programs and pharmaceutical partnerships. Ratings are subjective editorial opinions for each product’s stated purpose, not measured benchmarks.

Overview

Isomorphic Labs

Isomorphic Labs is an AI drug-design company developing therapeutics through internal programs and pharmaceutical partnerships. Its predictive and generative models support molecular design and in-silico experiments for small molecules and biologics. Scientists must select, test and validate candidates; a designed molecule is not an approved medicine.

Google AI Co-Scientist

Google AI co-scientist is a multi-agent research system that helps scientists develop, critique and rank hypotheses and experimental proposals. Specialized generation, reflection, ranking, evolution and review agents iterate on a scientist’s goal. The output supports research planning; experimental validation and scientific conclusions remain human responsibilities.

Editorial ratings · 1–10, higher is better

These scores express our judgement of the cited product facts. They are not measured performance benchmarks. Each product is assessed for its stated purpose; a higher score does not make different workflows interchangeable.

Evidence gaps lower confidence and affect the relevant judgement. Unknown pricing does not mean free access. Research prototypes and retired products retain their historical scope, with adoption ratings reflecting current access.

Ratings assessed: 2026-11-07. Source verification dates may differ.

Documented capability: How useful and complete is the documented workflow for the product's stated purpose?

  • 1–2: No usable current workflow established, or only an unsupported promise.
  • 3–4: Historical, experimental or very limited workflow; substantial delivery gaps.
  • 5–6: Concrete but narrow workflow, or promising research requiring specialist review.
  • 7–8: Substantial documented end-to-end workflow with useful controls or customization.
  • 9–10: Exceptionally complete documented scope and controls; reserve 10 for unusually strong evidence.

Ease of adoption: Can the intended user obtain and set up a usable product today?

  • 1–2: Discontinued, unavailable, waitlisted, or no usable deployment path verified.
  • 3–4: Archived software, restricted research/preorder access or uncertain current service access.
  • 5–6: Developer-managed setup, significant configuration or sales-led implementation.
  • 7–8: Active accessible product with manageable setup for its intended user.
  • 9–10: Straightforward self-service access and setup, with unusually few adoption obstacles.

Value and cost clarity: How attractive and understandable is the cost model for the documented use?

  • 1–2: No current purchasable or usable offer; historical prices cannot support a purchase.
  • 3–4: Material price, entitlement, license or availability uncertainty limits budgeting.
  • 5–6: Plausible value with custom pricing, significant setup costs or incomplete selected-plan terms.
  • 7–8: Useful scope with clear entry pricing/allowances or accessible source, while accounting for running costs.
  • 9–10: Exceptionally accessible and clear cost model for substantial useful scope; never assume free compute.

Integration options: How useful and extensible are the verified user-facing connections for the intended workflow?

  • 1–2: No current user-facing connection verified, or former connections are unavailable.
  • 3–4: Inputs/exports or one focused connection; internal dependencies are not native connectors.
  • 5–6: Useful API, configurable tools or several relevant connections, with limited verified breadth.
  • 7–8: Broad relevant connections or an extensible documented API/MCP/tool ecosystem.
  • 9–10: Extensive documented ecosystem with multiple connection mechanisms and strong task relevance.

Metrics Comparison

Documented capability

Google AI Co-Scientist: 6/10

Evidence confidence: high

Specialized generation, reflection, ranking, evolution and review agents iterate on a scientist’s goal. The output supports research planning; experimental validation and scientific conclusions remain human responsibilities.

Isomorphic Labs: 7/10

Evidence confidence: high

Its predictive and generative models support molecular design and in-silico experiments for small molecules and biologics. Scientists must select, test and validate candidates; a designed molecule is not an approved medicine.

The scores judge completeness for each stated purpose; different workflows are not interchangeable.

Ease of adoption

Google AI Co-Scientist: 3/10

Evidence confidence: high

Gemini Enterprise documents restricted preview access through a Google account team. Google Labs also offers an expression-of-interest route for Hypothesis Generation built with co-scientist; neither is ordinary unrestricted consumer access.

Isomorphic Labs: 3/10

Evidence confidence: high

This is a specialist research organization and partnership route, not a self-service research assistant that an individual can subscribe to.

Access, setup and human responsibilities matter alongside features.

Value and cost clarity

Google AI Co-Scientist: 3/10

Evidence confidence: high

Preview access and commercial terms need confirmation with Google. A consumer Gemini subscription price is not a verified price for co-scientist.

Isomorphic Labs: 3/10

Evidence confidence: high

Commercial collaborations have negotiated terms. There is no public per-seat software offer to use as a purchasing comparison.

Compare the full cost of your intended workflow, including external services and implementation.

Integration options

Google AI Co-Scientist: 4/10

Evidence confidence: high

The documented access path is Gemini Enterprise, with optional Cloud Logging for runs. This does not establish general-purpose Teams, GitHub or email connectors for the research system.

Isomorphic Labs: 3/10

Evidence confidence: high

Pharmaceutical partnerships are research collaborations, not software connectors. A public general-purpose drug-design API is not part of the published offer.

Choose the connections your workflow needs, rather than counting partner logos.

Conclusions

Consider co-scientist for hypothesis development if your research organization can obtain preview access and validate the resulting proposals.

Consider Isomorphic Labs in the context of pharmaceutical research partnerships, not as an immediately available desktop or web agent.

YOUR BRAND · YOUR CUSTOMERS · YOUR AI BUSINESS

Sell AI employees under your own brand.

Give businesses AI teams that own ongoing roles. Set your pricing, delegate routine coordination and build a recurring service.